Abstract
BackgroundChikungunya virus (CHIKV) has caused worldwide epidemics that impose a major burden on health systems. Approximately half of infected individuals develop chronic debilitating arthralgia, affecting their quality of life. Here, we identified the relevant clinical and demographic variables in the acute phase of CHIKV infection prospectively linked to chronic arthralgia to elaborate a prognostic scoring system.MethodsAcute CHIKV infection cases (n = 134) confirmed by serology or molecular test were examined <10 days of disease onset and followed for one year to evaluate for disease progression. Potential risk factors for chronic arthralgia were evaluated by multivariate analysis to develop a prognostic scoring system, which was subsequently tested in an independent validation cohort consisting of 42 individuals.ResultsA total of 107 out of 134 (80%) acute CHIKV-confirmed cases from the derivation cohort were re-examined one year after enrollment. Chronic arthralgia post-CHIKV infection was diagnosed in 64 (60%). Five of the 12 parameters evaluated in the acute phase were statistically associated with persistent arthralgia and were further tested by Bayesian analysis. These variables were weighted to yield a prognosis score denominated SHERA (Sex, Hypertension, Edema, Retroocular pain, Age), which exhibited 81.3% accuracy in predicting long-term arthralgia post-CHIKV infection in the derivation cohort, and 76.5% accuracy in the validation cohort.ConclusionsThe simplified and externally validated prognostic scoring system, SHERA, is a useful method to screen acutely CHIKV-infected patients at elevated risk of chronic arthralgia who will benefit from specific interventions. This tool could guide public health policies, particularly in resource-constrained settings.
Highlights
Debilitating manifestations are attributed to infection by the arthritogenic chikungunya alphavirus (CHIKV)
Potential risk factors for chronic arthralgia were evaluated by multivariate analysis to develop a prognostic scoring system, which was subsequently tested in an independent validation cohort consisting of 42 individuals
The simplified and externally validated prognostic scoring system, SHERA, is a useful method to screen acutely Chikungunya virus (CHIKV)-infected patients at elevated risk of chronic arthralgia who will benefit from specific interventions
Summary
Debilitating manifestations are attributed to infection by the arthritogenic chikungunya alphavirus (CHIKV). Until early 2000, sporadic outbreaks of chikungunya had been reported in Africa and South Asia.[1] After 2004, the virus spread to Europe and the Americas, highlighting potential for worldwide CHIKV dissemination.[2,3] In Brazil, several outbreaks have been reported since the first case in 2014, with progressively higher numbers of affected individuals with every successive epidemic.[4]. Chikungunya virus (CHIKV) has caused worldwide epidemics that impose a major burden on health systems. Half of infected individuals develop chronic debilitating arthralgia, affecting their quality of life. We identified the relevant clinical and demographic variables in the acute phase of CHIKV infection prospectively linked to chronic arthralgia to elaborate a prognostic scoring system
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have